Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689516 | 0.95 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL29760494 | 0.95 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL19699358 | 0.95 | NR1H4 (0.94) | NR1H4HSD17B13 | |
| SCHEMBL19698933 | 0.93 | NR1H4 (0.79) | NR1H4HSD17B13 | |
| SCHEMBL24445681 | 0.93 | NR1H4 (0.79) | NR1H4HSD17B13 | |
| SCHEMBL19690235 | 0.93 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL29386539 | 0.93 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL19698931 | 0.93 | NR1H4 (0.93) | NR1H4HSD17B13 | |
| SCHEMBL19699361 | 0.92 | NR1H4 (0.91) | NR1H4HSD17B13 | |
| SCHEMBL19699362 | 0.92 | NR1H4 (0.91) | NR1H4HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833150-B2 | Methods of treating liver disease | GILEAD SCIENCES, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3587412-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20180133203-A1 | METHODS OF TREATING LIVER DISEASE | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739065-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 681/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 681/4885 |
| US-11833150-B2 | Methods of treating liver disease | SLC10A1, FABP1, SLC10A2 | NR1H4 4/4885HSD17B13 200/4885 |
| US-20180133203-A1 | METHODS OF TREATING LIVER DISEASE | SLC10A1, FXR1, SLC10A2 | NR1H4 4/4885HSD17B13 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.